Amgen Sees Growing Institutional Support Amid Fluctuating Stock Price

Amgen Inc., NASDAQ: AMGN, a global biotechnology company, has received significant attention from institutional investors. Segall Bryant & Hamill LLC, for instance, purchased a new position in Amgen during the first quarter, acquiring 23,026 shares valued at approximately $8,696,000.

Several other institutional investors have also increased their stakes in Amgen. Brighton Jones LLC boosted its holdings by 23.5% in the fourth quarter, while Sivia Capital Partners LLC and Schnieders Capital Management LLC raised their positions in the second quarter. Main Street Financial Solutions LLC and Ieq Capital LLC also increased their holdings in Amgen during the same period.

The medical research company's stock price has seen some fluctuations, with shares opening at $385.16 on Monday. Its market cap stands at approximately $207.87 billion, with a price-to-earnings ratio of 26.80 and a beta of 0.41. Amgen's dividend payout ratio is currently 70.15%, supporting its income appeal.

Amgen has a history of earnings beats, but investors will scrutinize product-sales trends, guidance, and progress on MariTide in the company's upcoming second-quarter results.